Home/Filings/4/0001062993-23-022481

4//SEC Filing

CRANDELL KEITH 4

Accession 0001062993-23-022481

CIK 0001885522other

View on SEC.gov Company Profile

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 7:53 PM ET

Size

22.4 KB

Accession

0001062993-23-022481

Insider Transaction Report

Form 4

Period: 2023-12-08

Neumora Therapeutics, Inc.NMRA

GILLIS STEVEN

10% Owner

Transactions

Other
Common Stock
2023-12-08+1,176,593→ 2,321,566 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Other
Common Stock
2023-12-08+703,061→ 1,387,228 total(indirect: By ARCH Venture Fund VII, L.P.)

Holdings

Common Stock
(indirect: By ARCH Venture Fund X, L.P.)
12,205,379
Common Stock
(indirect: By ARCH Venture Fund X Overage, L.P.)
11,886,758
Common Stock
(indirect: By ARCH Venture Fund XII, L.P.)
4,131,207

ARCH Venture Partners XII, LLC

10% Owner

Transactions

Other
Common Stock
2023-12-08+703,061→ 1,387,228 total(indirect: By ARCH Venture Fund VII, L.P.)
Other
Common Stock
2023-12-08+1,176,593→ 2,321,566 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)

Holdings

Common Stock
(indirect: By ARCH Venture Fund X, L.P.)
12,205,379
Common Stock
(indirect: By ARCH Venture Fund XII, L.P.)
4,131,207
Common Stock
(indirect: By ARCH Venture Fund X Overage, L.P.)
11,886,758

ARCH Venture Partners XII, L.P.

10% Owner

Transactions

Other
Common Stock
2023-12-08+1,176,593→ 2,321,566 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Other
Common Stock
2023-12-08+703,061→ 1,387,228 total(indirect: By ARCH Venture Fund VII, L.P.)

Holdings

Common Stock
(indirect: By ARCH Venture Fund XII, L.P.)
4,131,207
Common Stock
(indirect: By ARCH Venture Fund X, L.P.)
12,205,379
Common Stock
(indirect: By ARCH Venture Fund X Overage, L.P.)
11,886,758

NELSEN ROBERT

10% Owner

Transactions

Other
Common Stock
2023-12-08+1,176,593→ 2,321,566 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)
Other
Common Stock
2023-12-08+703,061→ 1,387,228 total(indirect: By ARCH Venture Fund VII, L.P.)

Holdings

Common Stock
(indirect: By ARCH Venture Fund X, L.P.)
12,205,379
Common Stock
(indirect: By ARCH Venture Fund X Overage, L.P.)
11,886,758
Common Stock
(indirect: By ARCH Venture Fund XII, L.P.)
4,131,207

BYBEE CLINTON

10% Owner

Transactions

Other
Common Stock
2023-12-08+703,061→ 1,387,228 total(indirect: By ARCH Venture Fund VII, L.P.)
Other
Common Stock
2023-12-08+1,176,593→ 2,321,566 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)

Holdings

Common Stock
(indirect: By ARCH Venture Fund X, L.P.)
12,205,379
Common Stock
(indirect: By ARCH Venture Fund XII, L.P.)
4,131,207
Common Stock
(indirect: By ARCH Venture Fund X Overage, L.P.)
11,886,758

ARCH Venture Fund XII, L.P.

10% Owner

Transactions

Other
Common Stock
2023-12-08+703,061→ 1,387,228 total(indirect: By ARCH Venture Fund VII, L.P.)
Other
Common Stock
2023-12-08+1,176,593→ 2,321,566 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)

Holdings

Common Stock
(indirect: By ARCH Venture Fund XII, L.P.)
4,131,207
Common Stock
(indirect: By ARCH Venture Fund X, L.P.)
12,205,379
Common Stock
(indirect: By ARCH Venture Fund X Overage, L.P.)
11,886,758

CRANDELL KEITH

10% Owner

Transactions

Other
Common Stock
2023-12-08+703,061→ 1,387,228 total(indirect: By ARCH Venture Fund VII, L.P.)
Other
Common Stock
2023-12-08+1,176,593→ 2,321,566 total(indirect: By ARCH Venture Fund VIII Overage, L.P.)

Holdings

Common Stock
(indirect: By ARCH Venture Fund XII, L.P.)
4,131,207
Common Stock
(indirect: By ARCH Venture Fund X, L.P.)
12,205,379
Common Stock
(indirect: By ARCH Venture Fund X Overage, L.P.)
11,886,758

Footnotes (7)

[F1]Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares.
[F2]Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
[F3]Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
[F4]Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
[F5]Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
[F6]ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.
[F7]Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Documents

1 file

4
form4.xmlPrimary
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

→

Entity typeother

Related Parties

filerCIK 0001219039

Filing Metadata

Form type: 4
Filed: Dec 11, 7:00 PM ET
Accepted: Dec 12, 7:53 PM ET
Size: 22.4 KB

View on SEC.gov